在患有第一个ST段升高心肌梗塞的患者中,用于心血管疾病的初级预防,使用他类药物:马来西亚回顾性队列研究
Abdullah Faiz Zaihan1,2, Shairyzah Ahmad Hisham3, Aina Yazrin Ali Nasiruddin3
1Department of Pharmacy Shah Alam Hospital Shah Alam Selangor Malaysia.
Health science reports
|March 5, 2025
概括
对于心血管疾病 (CVD) 的初级预防,在患者首次ST升高心肌梗塞 (STEMI) 发生之前,他类药物治疗的使用不足. 高血压和脂质失调与他类药物使用有关,强调需要提高认识和遵守指导方针.
科学领域:
- 心脏病学 心脏病学
- 预防医学 预防医学
- 药物治疗 药物治疗
背景情况:
- 心血管疾病 (CVD) 仍然是导致死亡的主要原因.
- 包括他类药物治疗在内的初级预防策略对于减少心血管疾病事件至关重要.
- ST升高心肌梗塞 (STEMI) 是心血管疾病的一个关键表现.
研究的目的:
- 确定他类药物治疗用于心血管疾病初级预防的利用率.
- 确定在患者首次STEMI之前与他类药物使用相关的因素.
- 评估他类药物治疗在管理STEMI后脂质水平方面的有效性.
主要方法:
- 追溯队列研究的设计.
- 包括2020年在马来西亚一家医院接受首次STEMI治疗的177名患者.
- 后勤回归分析以确定他类药物使用的预测因素.
主要成果:
- 只有15.8%的患者在第一次STEMI之前接受了用于初级心血管疾病预防的他类药物治疗.
- 高血压 (AOR:9.570) 和脂质失调 (AOR:37.900) 是使用他类药物的显著预测因素.
- 在STEMI后,他类药物治疗显示显著降低胆固醇.
结论:
- 对于初级心血管疾病预防,在首次经历STEMI的患者中,他类药物治疗的利用率很低.
- 需要提高意识,遵守指导方针,并优化LDL-C向.
- 立方体治疗有效降低胆固醇水平,强调其在心血管疾病预防中的重要性.
更多相关视频
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
25.4K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.3K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
506
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
506
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437